RT Journal Article
SR Electronic
T1 Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.11.21264863
DO 10.1101/2021.10.11.21264863
A1 Lee, Katharine MN
A1 Junkins, Eleanor J
A1 Luo, Chongliang
A1 Fatima, Urooba A
A1 Cox, Maria L
A1 Clancy, Kathryn BH
YR 2022
UL http://medrxiv.org/content/early/2022/02/11/2021.10.11.21264863.abstract
AB Early in 2021, many people began sharing that they experienced unexpected menstrual bleeding after SARS-CoV-2 inoculation. We investigated this emerging phenomenon of changed menstrual bleeding patterns among a convenience sample of currently and formerly menstruating people using a web-based survey. In this sample, 42% of people with regular menstrual cycles bled more heavily than usual while 44% reported no change after being vaccinated. Among respondents who typically do not menstruate, 71% of people on long-acting reversible contraceptives, 39% of people on gender-affirming hormones, and 66% of post-menopausal people reported breakthrough bleeding. We found increased/breakthrough bleeding was significantly associated with age, systemic vaccine side effects (fever, fatigue), history of pregnancy or birth, and ethnicity. Generally, changes to menstrual bleeding are not uncommon nor dangerous, yet attention to these experiences is necessary to build trust in medicine.Teaser Increased bleeding can occur post SARS-CoV-2 vaccines; this study investigates patterns in who experiences these changes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by the University of Illinois Beckman Institute for Advanced Science and Technology, the University of Illinois Interdisciplinary Health Sciences Institute, NIH T32CA190194 (MPI: Colditz/James), and by the Foundation for Barnes-Jewish Hospital and by Siteman Cancer Center (KMNL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was designated as exempt by the University of Illinois Institutional Review Board and Washington University in St. Louis Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon appropriate request in combination with a data use agreement.